Statins and dilated cardiomyopathy: Do we have enough data?

Expert Opinion on Investigational Drugs

Volumn 20, Issue 3, 2011, Pages 315-323

  Bielecka Dabrowa, Agata ^a   Mikhailidis, Dimitri P ^b   Hannam, Simon ^c   Aronow, Wilbert S ^d   Rysz, Jacek ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

dilated cardiomyopathy; heart failure; statins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; DIGITALIS; DIURETIC AGENT; ETANERCEPT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

APOPTOSIS; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; ELECTROCARDIOGRAM; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; CARDIOMYOPATHY, DILATED; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; VENTRICULAR FUNCTION, LEFT;

EID: 79951606698     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.550570     Document Type: Review

References (72)

1. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol 1993;22:21-31
2. Merlet P, Benvenuti CH, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23 (Pubitemid 29269210)
3. Thaik CM, Calderone A, Takahashi A, Colucci WS. Interleukin-1b modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995;96:1093-9
4. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627-35 (Pubitemid 27432751)
5. Prabhu S. Cytokine-modulation of cardiac function. Circ Res 2004;95:1140-53
6. Bielecka-Dabrowa A, Wierzbicka M, Goch JH. Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target. Wiad Lek 2007;60:433-8
7. Banach M, Drozdz J, Okonski P, Rysz J. Immunological aspects of the statins' function in patients with heart failure: a report from the Annual Conference of ESC - Heart Failure 2005. Cell Mol Immunol 2005;2:433-7
8. De Gennaro L, Brunetti ND, Cuculo A, et al. Systemic inflammation in nonischemic dilated cardiomyopathy. Heart Vessels 2008;23:445-50
9. Lindberg E, Magnusson Y, Karason K, Andersson B. Lower levels of the host protective IL-10 in DCM - a feature of autoimmune pathogenesis? Autoimmunity 2008;41:478-83
10. Mandi Y, Hogye M, Talha EM, et al. Cytokine production and antibodies against heat shock protein 60 in ardiomyopathies of different origins. Pathobiology 2000;68:150-8 (Pubitemid 32110324)
11. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602 (Pubitemid 38451714)
12. Louis A, Cleland JGF, Crabbe S, et al. Clinical trial update. Eur J Heart Fail 2002;3:381-7
13. Lisman KA, Stetson SJ, Koerner T, et al. The role of tumor necrosis factor - alpha in the treatment of congestive heart failure. Congestive Heart Fail 2002;8:275-9 (Pubitemid 35190552)
14. Calo L, De Ruvo E., Sette A, et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown) 2007;8:138-43 (Pubitemid 46294811)
15. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
16. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr 2010;50:114-18
17. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physiol 2005;32:697-701 (Pubitemid 41603148)
18. Zimmermann AV, Doehner W, Vaz Perez A, et al. The relationship between high-density lipoprotein, bacterial lipopolysaccharide, and tumour necrosis factor-alpha in patients with acute decompensated heart failure. Arch Med Sci 2008;4:380-5
19. Li JM, Gall NP, Grieve DJ, et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002;40:477-84
20. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-74 (Pubitemid 37187782)
21. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells. Circulation 2004;110:851-61
22. Yoon SJ, Yoon YW, Lee BK, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009;41:802-11
23. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hyroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure. Circulation 2001;104:982-5 (Pubitemid 32803872)
24. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physiol 2005;32:697-701 (Pubitemid 41603148)
25. Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006;47:770-9 (Pubitemid 44305251)
26. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002;39:957-62 (Pubitemid 34234116)
27. Sever PS, Dahlof B, Poulter NR, et al.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;64:43-60 (Pubitemid 39657106)
28. Spencer FA, Allegrone J, Goldberg RJ, et al.; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140:857-66
29. Pedersen TR, Kjekshus J, Berg K, et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004;5:81-7
30. Von Haehling S, Anker SD. Statins for heart failure: where to go from here? Arch Med Sci 2007;3:S133-41 (Pubitemid 351270823)
31. Ashton E, Windebank E, Skiba M, et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol; doi:10.1016/j.ijcard.2009.12.028
32. Kjekshus J, Apetrei A, Barrios V, et al.; and for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61 (Pubitemid 350190755)
33. Tavazzi L, Maggioni AP, Marchioli R, et al.; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9
34. Gurguna C, Ildizli M, Yavuzgil O, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008;123:102-7 (Pubitemid 350250883)
35. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004;43:642-8 (Pubitemid 38229538)
36. Emberson JR, Ng LL, Armitage J. Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007;49:311-19
37. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7 (Pubitemid 43063250)
38. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006;97:899-904
39. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43 (Pubitemid 37022126)
40. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone following high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006;47:338-41 (Pubitemid 43063251)
41. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009;15:MS12-23
42. Haugen E, Gan LM, Isic A, et al. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol 2008;13:19-24 (Pubitemid 351425258)
43. Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1-7 (Pubitemid 46330836)
44. Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta- blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 2007;99:1448-50 (Pubitemid 46686650)
45. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987;60:1340-55
46. Dubner S, Valero E, Pesce R, et al. A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study. Ann Noninvasive Electrocardiol 2005;10:420-8 (Pubitemid 43942701)
47. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000;36:766-72
48. Mitchell LB, Powell JL, Gillis AM, et al.; AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003;42:81-7 (Pubitemid 36760765)
49. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007;153:573-8 (Pubitemid 46440697)
50. Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:769-73 (Pubitemid 43243099)
51. Goldberger JJ, Subacius H, Schaechter A, et al.; DEFINITE Investigators. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1228-33 (Pubitemid 44363151)
52. Dulak E, Lubinski A, Bissinger A, et al. Recurrence of ventricular arrhythmias in patients with non-ischaemic dilated cardiomyopathy: evidence-based predictors. Kardiol Pol 2009;67:837-44
53. Hanna IR, Heeke B, Bush H, et al. Lipid - lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhytm 2006;3:881-6 (Pubitemid 44103516)
54. Kowalski J, Barylski M, Banach M, et al. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006;48:143-7 (Pubitemid 44691215)
55. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25:1995-2005
56. Stypmann J, Schubert A, Welp H, et al. Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol 2008;31:478-81
57. Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther 2009;23:369-76
58. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005;91:27-31 (Pubitemid 39664987)
59. Hofer J, Niebauer J. Cardiovascular risk factors: lipids and lifestyle changes. Arch Med Sci 2007;3:S69-73 (Pubitemid 351270814)
60. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005;11:684-90 (Pubitemid 41797497)
61. Gentlesk PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 2005;150:478-83 (Pubitemid 41317617)
62. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-16
63. Wachtell K. Hypertensive heart disease: left ventricular hypertrophy. Arch Med Sci 2009;5:S300-9
64. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
65. Aydin U, Ugurlucan M, Gungor F, et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology 2009;60:370-7
66. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol-lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? Arch Med Sci 2009;5:289-95
67. Ramasubbu K, Farmer JA. The role of statin therapy in the management of cardiomyopathies. Curr Atheroscler Rep 2009;11:118-23
68. Yamada T, Node K, Mine T, et al. Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy. Am J Med Sci 2006;332:361-3 (Pubitemid 46005833)
69. Sakamoto T, Kojima S, Ogawa H, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006;97:1165-71
70. Bielecka-Dabrowa A, Goch JH, Rysz J, et al. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Lipids Health Dis 2010;9:21
71. Angelopoulos J, Krassakopoulos N, Nathanson R, et al. Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci 2009;5:347-63
72. Trochu JN, Mital S, Zhang X, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003;60:250-8 (Pubitemid 37412358)